Atea Pharmaceuticals reported Q1 2026 financial results and progress on its antiviral drug programs. The company is on track for topline results from its Phase 3 trials of bemnifosbuvir and ruzasvir for Hepatitis C by mid and end of 2026. These drugs show promise as a potentially best-in-class treatment with high efficacy and convenience. Additionally, Atea plans to start Phase 1 trials mid-2026 for AT-587, a potential first-in-class therapy for Hepatitis E, addressing a critical unmet need. Financially, Atea ended Q1 with $256 million in cash and increased R&D spending to support these programs.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
